Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MLYS Mineralys Therapeutics	$14.00 -1.7%	$14.87	$8.24 ▼ $18.38	$928.10M	-0.17	536,928 shs	511,588 shs
NRIX Nurix Therapeutics	$11.84 +1.9%	$11.00	$8.18 ▼ $29.56	$885.86M	2.15	844,777 shs	428,293 shs
TVGN Semper Paratus Acquisition	$1.18 +0.9%	$1.16	$0.26 ▼ $3.09	$215.15M	-0.69	5.04 million shs	118,019 shs
ZYME Zymeworks	$12.37 -2.7%	$12.16	$8.27 ▼ $17.70	$860.67M	1.17	580,992 shs	301,420 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MLYS Mineralys Therapeutics	-1.69%	+1.97%	-11.00%	-4.50%	+26.24%
NRIX Nurix Therapeutics	+1.89%	+1.89%	+21.19%	-2.55%	-42.13%
TVGN Semper Paratus Acquisition	+0.85%	-1.67%	-8.53%	-1.67%	+57.33%
ZYME Zymeworks	-2.68%	-2.06%	+10.25%	0.00%	+47.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership
MLYS Mineralys Therapeutics	2.9203 of 5 stars	3.4	3.0	2.3	4.2
NRIX Nurix Therapeutics	1.3385 of 5 stars	3.4	1.0	2.0	0.8
TVGN Semper Paratus Acquisition	3.9428 of 5 stars	3.5	4.0	2.2	2.5
ZYME Zymeworks	1.674 of 5 stars	3.5	0.0	1.7	3.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	130.36% Upside
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.18	154.87% Upside
TVGN Semper Paratus Acquisition	3.00	Buy	$7.10	501.69% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.00	69.77% Upside

Current Analyst Ratings Breakdown

Latest TVGN, MLYS, NRIX, and ZYME Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
6/10/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/20/2025	ZYME Zymeworks	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/12/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
NRIX Nurix Therapeutics	$54.55M	16.55	N/A	N/A	$7.44 per share	1.59
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	($0.09) per share	N/A
ZYME Zymeworks	$93.38M	9.22	N/A	N/A	$6.63 per share	1.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-369.40%	-47.49%	-36.10%	7/10/2025 (Estimated)
TVGN Semper Paratus Acquisition	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-934.56%	8/4/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$1.49	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	7/30/2025 (Estimated)

Latest TVGN, MLYS, NRIX, and ZYME Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.73	N/A	N/A	N/A	$16.26 million	N/A
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	N/A	ZYME Zymeworks	-$0.45	-$0.30	+$0.15	N/A	$20.65 million	$27.11 million
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MLYS Mineralys Therapeutics	N/A	26.48	26.48
NRIX Nurix Therapeutics	N/A	6.26	6.26
TVGN Semper Paratus Acquisition	N/A	0.35	0.35
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MLYS Mineralys Therapeutics	84.46%
NRIX Nurix Therapeutics	N/A
TVGN Semper Paratus Acquisition	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
MLYS Mineralys Therapeutics	25.56%
NRIX Nurix Therapeutics	7.40%
TVGN Semper Paratus Acquisition	73.24%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
NRIX Nurix Therapeutics	300	76.24 million	70.60 million	Optionable
TVGN Semper Paratus Acquisition	3	183.89 million	49.21 million	N/A
ZYME Zymeworks	460	69.58 million	67.56 million	Optionable

TVGN, MLYS, NRIX, and ZYME Headlines

Recent News About These Companies

Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

June 25 at 3:35 AM | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus Price Target from Brokerages

June 24 at 2:16 AM | americanbankingnews.com

Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

June 20, 2025 | zacks.com

Rhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)

June 20, 2025 | marketbeat.com

Duncan Williams Asset Management LLC Buys Shares of 22,095 Zymeworks Inc. (NYSE:ZYME)

June 19, 2025 | marketbeat.com

Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500

June 18, 2025 | kalkinemedia.comK

SG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME)

June 17, 2025 | marketbeat.com

Assenagon Asset Management S.A. Sells 147,184 Shares of Zymeworks Inc. (NYSE:ZYME)

June 15, 2025 | marketbeat.com

Zymeworks (NYSE:ZYME) Shares Gap Down - Time to Sell?

June 13, 2025 | marketbeat.com

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

June 12, 2025 | seekingalpha.com

Bank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME)

June 12, 2025 | marketbeat.com

Wellington Management Group LLP Decreases Position in Zymeworks Inc. (NYSE:ZYME)

June 5, 2025 | marketbeat.com

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

June 4, 2025 | zacks.com

Zymeworks’ zanidatamab gains approval in China for biliary tract cancer

June 2, 2025 | msn.com

Zymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLC

June 2, 2025 | marketbeat.com

Voloridge Investment Management LLC Buys Shares of 43,708 Zymeworks Inc. (NYSE:ZYME)

May 31, 2025 | marketbeat.com

Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone

May 30, 2025 | endpts.comE

China's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract Cancer

May 30, 2025 | precisionmedicineonline.comP

Zymeworks’ zanidatamab approved in China

May 30, 2025 | thepharmaletter.comT

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge

May 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, MLYS, NRIX, and ZYME Company Descriptions

Mineralys Therapeutics NASDAQ:MLYS

$14.00 -0.24 (-1.69%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$14.03 +0.03 (+0.21%)

As of 06/26/2025 04:23 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Nurix Therapeutics NASDAQ:NRIX

$11.84 +0.22 (+1.89%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$11.82 -0.02 (-0.13%)

As of 06/26/2025 04:09 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Semper Paratus Acquisition NASDAQ:TVGN

$1.18 +0.01 (+0.85%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.18 0.00 (0.00%)

As of 08:21 AM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Zymeworks NYSE:ZYME

$12.37 -0.34 (-2.68%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$12.69 +0.32 (+2.55%)

As of 07:27 AM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time